As the result of a rhJNK1 HTS, the imidazo[1,2-a]quinoxaline 1 was identified as a 1.6 μM rhJNK1 inhibitor. Optimization of this compound lead to AX13587 (rhJNK1 IC50=160 nM) which was co-crystallized with JNK1 to identify key molecular interactions. Kinase profiling against 125+ kinases revealed AX13587 was an inhibitor of JNK, MAST3, and MAST4 whereas its methylene homolog AX14373 (native JNK1 IC50=47 nM) was a highly specific JNK inhibitor.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2013.06.087 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Deep Multitask Learning-Driven Discovery of New Compounds Targeting .
ACS Omega
December 2024
Laboratory of Cheminformatics, Faculty of Pharmacy, Universidade Federal de Goiás, Goiânia 74605-170, Brazil.
Article Synopsis
- Visceral leishmaniasis is a serious disease primarily found in low- and middle-income countries, with limited treatment options due to toxicity and drug resistance.
- Researchers developed a multitask learning (MTL) pipeline to predict the effectiveness of compounds against several species, screening about 1.3 million compounds and finding 20 potential candidates with significant antileishmanial activity.
- Three of these compounds showed strong efficacy and moderate safety, suggesting they could lead to new therapies, while the use of explainable models aids in understanding how these compounds work, potentially improving drug discovery for neglected tropical diseases.
Novel Naphthyridones Targeting Pannexin 1 for Colitis Management.
Adv Sci (Weinh)
December 2024
Institute of Biotechnology, National Tsing Hua University, Hsinchu, 300044, Taiwan.
Pannexin 1 (PANX1) forms cell-surface channels capable of releasing signaling metabolites for diverse patho-physiological processes. While inhibiting dysregulated PANX1 has been proposed as a therapeutic strategy for many pathological conditions, including inflammatory bowel disease (IBD), low efficacy, or poor specificity of classical PANX1 inhibitors introduces uncertainty for their applications in basic and translational research. Here, hit-to-lead optimization is performed and a naphthyridone, compound 12, is identified as a new PANX1 inhibitor with an IC of 0.
View Article and Find Full Text PDFOptimization of Potent and Selective Cyclohexyl Acid ERAP1 Inhibitors Using Structure- and Property-Based Drug Design.
ACS Med Chem Lett
December 2024
National Center for Scientific Research "Demokritos", Agia Paraskevi, Attiki 15341, Greece.
Endoplasmic reticulum aminopeptidase 1 (ERAP1) cleaves the -terminal amino acids of peptides, which can then bind onto major histocompatibility class I (MHC-I) molecules for presentation onto the cell surface, driving the activation of adaptive immune responses. In cancer, overtrimming of mature antigenic peptides can reduce cytotoxic T-cell responses, and ERAP1 can generate self-antigenic peptides which contribute to autoimmune cellular responses. Therefore, modulation of ERAP1 activity has potential therapeutic indications for cancer immunotherapy and in autoimmune disease.
View Article and Find Full Text PDFGuardians at the Gate: Optimization of Small Molecule Entry Inhibitors of Ebola and Marburg Viruses.
J Med Chem
January 2025
UICentre: Drug Discovery, University of Illinois Chicago, Chicago, Illinois 60612, United States.
Ebola and Marburg (EBOV and MARV) filoviral infections lead to fatal hemorrhagic fevers and have caused over 30 outbreaks in the last 50 years. Currently, there are no FDA-approved small molecule therapeutics for effectively treating filoviral diseases. To address this unmet medical need, we have conducted a systematic structural optimization of an early lead compound, -(4-(4-methylpiperidin-1-yl)-3-(trifluoromethyl)phenyl)-4-(morpholinomethyl)benzamide (), borne from our previously reported hit-to-lead effort.
View Article and Find Full Text PDFSmall-molecule inhibition of SARS-CoV-2 NSP14 RNA cap methyltransferase.
Nature
December 2024
Laboratory for RNA Molecular Biology, The Rockefeller University, New York, NY, USA.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The rapid development of highly effective vaccines against SARS-CoV-2 has altered the trajectory of the pandemic, and antiviral therapeutics have further reduced the number of COVID-19 hospitalizations and deaths. Coronaviruses are enveloped, positive-sense, single-stranded RNA viruses that encode various structural and non-structural proteins, including those critical for viral RNA replication and evasion from innate immunity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!